Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by State Street Corp

State Street Corp increased its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL) by 102.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,340,042 shares of the company’s stock after acquiring an additional 1,182,181 shares during the quarter. State Street Corp’s holdings in Replimune Group were worth $25,647,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Nisa Investment Advisors LLC increased its holdings in shares of Replimune Group by 10,304.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after purchasing an additional 4,946 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Replimune Group by 10.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 180,226 shares of the company’s stock valued at $1,622,000 after acquiring an additional 17,471 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of Replimune Group by 7.2% in the second quarter. Rhumbline Advisers now owns 84,923 shares of the company’s stock valued at $764,000 after purchasing an additional 5,732 shares during the period. TD Asset Management Inc increased its position in Replimune Group by 4.6% during the second quarter. TD Asset Management Inc now owns 249,940 shares of the company’s stock worth $2,249,000 after purchasing an additional 11,094 shares during the last quarter. Finally, Arizona State Retirement System purchased a new position in Replimune Group during the second quarter worth about $108,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Insider Buying and Selling at Replimune Group

In other news, insider Konstantinos Xynos sold 7,246 shares of the stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the transaction, the insider now owns 109,885 shares in the company, valued at approximately $1,184,560.30. This represents a 6.19 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Sushil Patel sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $12.42, for a total value of $124,200.00. Following the sale, the chief executive officer now directly owns 202,014 shares in the company, valued at $2,509,013.88. This trade represents a 4.72 % decrease in their position. The disclosure for this sale can be found here. Insiders own 8.80% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on REPL shares. Jefferies Financial Group upped their price objective on Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, December 4th. HC Wainwright reaffirmed a “buy” rating and issued a $17.00 target price on shares of Replimune Group in a research report on Friday, November 22nd. JPMorgan Chase & Co. lifted their price target on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, September 24th. Roth Mkm initiated coverage on shares of Replimune Group in a research report on Tuesday, August 27th. They set a “buy” rating and a $17.00 price objective for the company. Finally, BMO Capital Markets boosted their target price on Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a research report on Friday, November 22nd. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $17.29.

Replimune Group Trading Up 4.0 %

NASDAQ:REPL opened at $12.49 on Monday. The stock has a fifty day moving average price of $12.25 and a 200 day moving average price of $10.77. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18. Replimune Group, Inc. has a 12-month low of $4.92 and a 12-month high of $17.00. The firm has a market cap of $854.53 million, a PE ratio of -4.10 and a beta of 1.26.

Replimune Group (NASDAQ:REPL) last released its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. Sell-side analysts anticipate that Replimune Group, Inc. will post -2.91 earnings per share for the current fiscal year.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.